Vazyme Biotech Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 3,002

Employees

  • Stock Symbol
  • 688105

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $3.16
  • (As of Friday Closing)

Vazyme Biotech General Information

Description

Nanjing Vazyme Biotech Co Ltd is engaged in conducting technological research and product development focusing on functional proteins such as enzymes, antigens, and antibodies, as well as high molecular weight organic materials.

Contact Information

Website
www.vazyme.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Building C2, Hongfeng Science and Technology Park
  • Kechuang Road, Nanjing Economic and Technological Development Zone
  • Nanjing, Jiangsu
  • China
+86 025
Primary Industry
Diagnostic Equipment
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • Building C2, Hongfeng Science and Technology Park
  • Kechuang Road, Nanjing Economic and Technological Development Zone
  • Nanjing, Jiangsu
  • China
+86 025

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vazyme Biotech Stock Performance

As of 13-Nov-2026, Vazyme Biotech’s stock price is $3.16. Its current market cap is $1.63B with 517M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.16 $3.43 $1.91 - $4.35 $1.63B 517M 13.8M

Vazyme Biotech Financials Summary

As of 30-Sep-2026, Vazyme Biotech has a trailing 12-month revenue of $226M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,825,120 871,838 972,468 1,500,847
Revenue 225,837 191,603 192,029 181,768
EBITDA (1,721) 16,512 14,400 3,445
Net Income 144 (2,310) (2,522) (10,029)
Total Assets 731,275 718,620 691,588 810,622
Total Debt 127,826 120,405 102,973 181,562
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vazyme Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vazyme Biotech‘s full profile, request access.

Request a free trial

Vazyme Biotech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Vazyme Biotech‘s full profile, request access.

Request a free trial

Vazyme Biotech Patents

Vazyme Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026188834-A1 Adapter oligonucleotide, linker oligonucleotide, and sequencing library construction method Pending 11-Mar-2025
WO-2026157441-A1 Method for preparing intermediate peptide of glp-1 peptide or analogue thereof Pending 21-Jan-2025
WO-2026157442-A1 Method for preparing intermediate peptide of glp-1 peptide or analogue thereof Pending 21-Jan-2025
WO-2026144572-A1 Transposase library construction method for reducing linker dimers in library Pending 02-Jan-2025
JP-2026010073-A Rna polymerase mutants and uses thereof Pending 14-Oct-2024 C12N9/1247
To view Vazyme Biotech’s complete patent history, request access »

Vazyme Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vazyme Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vazyme Biotech‘s full profile, request access.

Request a free trial

Vazyme Biotech Investments (2)

Vazyme Biotech’s most recent deal was a Early Stage VC with Huiliao for . The deal was made on 14-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Huiliao 14-Jan-2025 Early Stage VC Pharmaceuticals
CYGENTA (China) 25-Oct-2022 Early Stage VC BPO/Outsource Services
To view Vazyme Biotech’s complete investments history, request access »

Vazyme Biotech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Vazyme Biotech’s complete esg history, request access »

Vazyme Biotech FAQs

  • When was Vazyme Biotech founded?

    Vazyme Biotech was founded in 2012.

  • Where is Vazyme Biotech headquartered?

    Vazyme Biotech is headquartered in Nanjing, China.

  • What is the size of Vazyme Biotech?

    Vazyme Biotech has 3,002 total employees.

  • What industry is Vazyme Biotech in?

    Vazyme Biotech’s primary industry is Diagnostic Equipment.

  • Is Vazyme Biotech a private or public company?

    Vazyme Biotech is a Public company.

  • What is Vazyme Biotech’s stock symbol?

    The ticker symbol for Vazyme Biotech is 688105.

  • What is the current stock price of Vazyme Biotech?

    As of 13-Nov-2026 the stock price of Vazyme Biotech is $3.16.

  • What is the current market cap of Vazyme Biotech?

    The current market capitalization of Vazyme Biotech is $1.63B.

  • What is Vazyme Biotech’s current revenue?

    The trailing twelve month revenue for Vazyme Biotech is $226M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process